



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

RENNER *et al.*

Appl. No. 10/050,898

Filed: January 18, 2002

For: **Molecular Antigen Array**

Confirmation No. 7794

Art Unit: 1645

Examiner: *To be assigned*

Atty. Docket: 1700.0190005/BJD/SJE

Third Supplemental Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on November 27, 2002, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application

does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Third Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.




Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: April 8, 2003

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

FORM PTO-1449 <u>THIRD SUPPLEMENTAL</u> <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1700.0190005/BJD/SJE	APPLICATION NO. 10/050,898
	APPLICANT Renner <i>et al.</i>	
	FILING DATE January 18, 2002	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1	5,935,821	08/10/1999	Chatterjee <i>et al.</i>			11/21/1996
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP2	WO 99/28478	06/10/1999	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>79</u>	Kozlovska, T.M., <i>et al.</i> , "RNA Phage Q β Coat Protein as a Carrier for Foreign Epitopes," <i>Intervirology</i> 39:9-15, S. Karger AG (1996).
	AS	<u>79</u>	Kratz, P.A., <i>et al.</i> , "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," <i>Proc. Natl. Acad. Sci. USA</i> 96:1915-1920, National Academy of Sciences (1999).
	AT	<u>79</u>	Nieland, J.D., <i>et al.</i> , "Chimeric Papillomavirus Virus-like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response," <i>J. Cell. Biochem.</i> 73:145-152, Wiley-Liss, Inc. (1999).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>THIRD SUPPLEMENTAL</u> <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1700.0190005/BJD/SJE	APPLICATION NO. 10/050,898
	APPLICANT Renner et al.	
	FILING DATE January 18, 2002	GROUP 1645

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL3	WO 99/57289	11/11/1999	WIPO			Yes No
	AM3	WO 00/50461	08/31/2000	WIPO			Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>80</u>	Slepushkin, V.A., et al., "Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein," Vaccine 13:1399-1402, Elsevier Science Ltd. (1995).
AS	<u>80</u>	Vasiljeva, I., et al., "Mosaic Q β coats as a new presentation model," FEBS Lett. 431:7-11, Federation of European Biochemical Societies (1998).
AT	<u>80</u>	International Search Report for International Application No. PCT/IB 02/00166, mailed January 31, 2003, European Patent Office, Netherlands.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.